Q-omics provides the consensus-scored MARCHF1 profile across patient tissues and cancer cell-line models. MARCHF1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MARCHF1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MARCHF1 RNA expression shows 19,082 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where MARCHF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCHF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCHF1 survival associations across molecular data types. MARCHF1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCHF1 RNA expression–survival associations across cancer types. High MARCHF1 expression shows unfavorable associations in UVM, but favorable associations in SKCM, HNSC, LUAD, UCS and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MARCHF1 RNA expression.
This table summarizes MARCHF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MARCHF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCHF1 shows lower tumor expression in LUSC and higher tumor expression in KIRC, HNSC, KIRP, STAD and BRCA. The KIRC box plot shows higher MARCHF1 RNA expression in tumor versus normal tissue (log2 FC = +1.304, t-test p < 0.001).
This table shows molecular features associated with MARCHF1 in patient tissues and cancer cell lines. In patient samples, MARCHF1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MARCHF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
